The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg negative and anti-HBc positive), in order to prevent reverse seroconversion. Moreover it is suggested a strict adherence to criteria of allocation based on the virological characteristics of both recipients and donors in the general setting of transplants and in liver transplantation the universal prophylaxis with nucleos(t)ides analogues (frequently combined with specific anti-HBV immunoglobulins) in HBsAg positive candidates and in HBsAg negative recipients of anti-HBc positive grafts.

Marzano, A., Angelucci, E., Andreone, P., Brunetto, M., Bruno, R., Burra, P., et al. (2007). Prophylaxis and treatment of hepatitis B in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 39(5), 397-408 [10.1016/j.dld.2006.12.017].

Prophylaxis and treatment of hepatitis B in immunocompromised patients

Bruno R;Fagiuoli S;Puoti M;
2007

Abstract

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg negative and anti-HBc positive), in order to prevent reverse seroconversion. Moreover it is suggested a strict adherence to criteria of allocation based on the virological characteristics of both recipients and donors in the general setting of transplants and in liver transplantation the universal prophylaxis with nucleos(t)ides analogues (frequently combined with specific anti-HBV immunoglobulins) in HBsAg positive candidates and in HBsAg negative recipients of anti-HBc positive grafts.
Articolo in rivista - Review Essay
Antivirals; HBV; Immunosuppression; Transplants;
English
397
408
12
Marzano, A., Angelucci, E., Andreone, P., Brunetto, M., Bruno, R., Burra, P., et al. (2007). Prophylaxis and treatment of hepatitis B in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 39(5), 397-408 [10.1016/j.dld.2006.12.017].
Marzano, A; Angelucci, E; Andreone, P; Brunetto, M; Bruno, R; Burra, P; Caraceni, P; Daniele, B; Di Marco, V; Fabrizi, F; Fagiuoli, S; Grossi, P; Lampertico, P; Meliconi, R; Mangia, A; Puoti, M; Raimondo, G; Smedile, A
File in questo prodotto:
File Dimensione Formato  
marzano.pdf

Solo gestori archivio

Dimensione 177.49 kB
Formato Adobe PDF
177.49 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/354320
Citazioni
  • Scopus 198
  • ???jsp.display-item.citation.isi??? 187
Social impact